StockWatch
·
Biotechnology: Pharmaceutical Preparations
Clinical TrialNov 16, 2026, 09:16 AM

MetaVia: DA-1726 Shows Positive Preclinical Data vs. Retatrutide

AI Summary

MetaVia Inc. announced positive preclinical data comparing its novel dual GLP-1/glucagon receptor agonist, DA-1726, with retatrutide. The study in obese mice showed DA-1726 demonstrated greater glucose lowering and comparable weight loss to retatrutide, with less suppression of food intake. DA-1726 also increased hepatic Fgf21 expression and protein levels, suggesting a differentiated metabolic profile. The company plans to initiate a Phase 2 study in Metabolic and Alcohol-Associated Liver Disease (MetALD) and Alcohol-Associated Liver Disease (ALD) in the second half of 2027.

Key Highlights

  • MetaVia's DA-1726 showed increased hepatic Fgf21 expression and protein levels in preclinical study.
  • DA-1726 demonstrated greater glucose lowering (43.0% vs 21.5%) compared to retatrutide.
  • DA-1726 achieved comparable weight loss (41.7% vs 43.6%) with less food intake suppression.
  • DA-1726 showed favorable lipid metabolism effects, reducing total cholesterol by 69.3% vs 69.0% for retatrutide.
  • MetaVia plans to initiate a Phase 2 study for DA-1726 in MetALD and ALD in H2 2027.